A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

• Status: Recruiting
• Trial end date: 2030-08-16

Summary

A study comparing nivolumab and bacterial drugs given to help the body's immune system in the bladder versus bacterial drugs alone in high risk bladder cancer participants.

• Phase: Phase 3

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: BCG Vaccine; Nivolumab